Optimization of Breast Cancer Chemotherapy Regimens using a Pharmacokinetic/Pharmacodynamic Model-Based Design
- 29 Downloads
This review presents a new optimal model-based regimen for cytotoxic chemotherapy. The main purpose of designing this improved regimen was to minimize the adverse effects of chemotherapy on healthy tissue whilst still destroying tumour cells. By considering the Gompertzian model for tumour and normal cell growth, and simple models for drug pharmacokinetics and pharmacodynamics, a two-part cost function is defined and minimized subject to constraints defined by each patient’s physical condition. The response of the neutrophil cell population to the drug is modelled, together with the tumour response, and some features of this response are used as constraints. The proposed model-based regimen includes refined drug doses and administration intervals in each chemotherapy cycle.
KeywordsDoxorubicin Cost Function Neutrophil Count Plan Dose Cumulative Total Dose
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
- 2.Bojkov B, Hansel R, Luus R. Application of direct search optimization to optimal control problems. Hung J Ind Chem 1993; 21: 177–85Google Scholar
- 4.Khaloozadeh H, Homaei Shandiz F, Yazdanbakhsh P. The optimal dose of drug in neoadjuvant chemotherapy before surgery for patients suffering with breast cancer stage IIB. Singapore: IEEE-ICBME, 2005Google Scholar
- 5.BC Cancer Agency. Doxorubicin. In: Cancer drug manual revised. Vancouver (BC): BC Cancer Agency, 2006 AugGoogle Scholar
- 6.BC Cancer Agency. Cyclophosphamide. In: Cancer drug manual limited revision. Vancouver (BC): BC Cancer Agency, 2006 MarGoogle Scholar
- 7.Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002 July 15; 20 (14): 3114–21PubMedCrossRefGoogle Scholar
- 8.Radhakrishnan R. Formulation of population pharmacokinetic models of anti-cancer agents [thesis]. Pittsburgh (PA): University of Pittsburgh, 2004Google Scholar
- 9.Harrold JM. Model-based design of cancer chemotherapy treatment schedules [thesis]. Pittsburgh (PA): University of Pittsburgh, 2005Google Scholar
- 10.Atta H, Beijnen J, Vermorken JB, et al. Pharmacokinetics and pharmacodynamics of anticancer agents used in gynecological oncology. CME J Gynecol Oncol 2004 July; 5–16Google Scholar